Enrolling

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)

I5Q-MC-CGAT -

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
12 - 17 years
Conditions the trial is for
Migraine
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
300
Trial Dates
Nov 25, 2020 - Mar 2026
How long will I be in the trial?
The study will last about 77 weeks and may include up to 18 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Patients must have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 [2018]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month

Participants Must Not:

  • Participants must not be allergic to multiple drugs or certain types of drugs sometimes used for headaches

  • Participants must not have a history of persistent headaches every day or cluster headaches

  • Participants must not have a history of head or neck injury that was associated with the start of migraine headaches or a change in the nature of their headaches

  • Participants must not have a history of brain tumors or birth defects of the brain

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources